BBA
KURA icon

Baker Bros. Advisors’s Kura Oncology KURA Stock Holding History

Baker Bros. Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-274,458
Closed -$4.41M – 119
2022
Q1 		$4.41M Sell
274,458
-29,700
-10% -$429K 0.03% 89
2021
Q4 		$4.26M Hold
304,158
– – 0.02% 96
2021
Q3 		$5.7M Buy
+304,158
New +$5.73M 0.03% 90

Other funds holding KURA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Baker Bros. Advisors's KURA Position: Q2 2022 in Review

Baker Bros. Advisors sold out of Kura Oncology (KURA) in Q2 2022, closing a stake of 274,458 shares — an estimated $4.41M sold.

Baker Bros. Advisors first reported a position in KURA in Q3 2021 and held it in 3 quarters. The position peaked at $5.7M in Q3 2021. 148 funds tracked by Wall St. Rank hold KURA as of Q2 2022.

  • Baker Bros. Advisors reported no remaining Kura Oncology position as of Q2 2022 after selling out during the quarter.
  • Baker Bros. Advisors sold 274,458 Kura Oncology shares in Q2 2022, an estimated $4.41M.
  • Baker Bros. Advisors first reported a position in Kura Oncology in Q3 2021 and held it in 3 quarters.
  • Baker Bros. Advisors's Kura Oncology position peaked at $5.7M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2022.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.